» Articles » PMID: 35172826

Similarly Efficacious Anti-malarial Drugs SJ733 and Pyronaridine Differ in Their Ability to Remove Circulating Parasites in Mice

Abstract

Background: Artemisinin-based combination therapy (ACT) has been a mainstay for malaria prevention and treatment. However, emergence of drug resistance has incentivised development of new drugs. Defining the kinetics with which circulating parasitized red blood cells (pRBC) are lost after drug treatment, referred to as the "parasite clearance curve", has been critical for assessing drug efficacy; yet underlying mechanisms remain partly unresolved. The clearance curve may be shaped both by the rate at which drugs kill parasites, and the rate at which drug-affected parasites are removed from circulation.

Methods: In this context, two anti-malarials, SJ733, and an ACT partner drug, pyronaridine were compared against sodium artesunate in mice infected with Plasmodium berghei (strain ANKA). To measure each compound's capacity for pRBC removal in vivo, flow cytometric monitoring of a single cohort of fluorescently-labelled pRBC was employed, and combined with ex vivo parasite culture to assess parasite maturation and replication.

Results: These three compounds were found to be similarly efficacious in controlling established infection by reducing overall parasitaemia. While sodium artesunate acted relatively consistently across the life-stages, single-dose SJ733 elicited a biphasic effect, triggering rapid, partly phagocyte-dependent removal of trophozoites and schizonts, followed by arrest of residual ring-stages. In contrast, pyronaridine abrogated maturation of younger parasites, with less pronounced effects on mature parasites, while modestly increasing pRBC removal.

Conclusions: Anti-malarials SJ733 and pyronaridine, though similarly efficacious in reducing overall parasitaemia in mice, differed markedly in their capacity to arrest replication and remove pRBC from circulation. Thus, similar parasite clearance curves can result for anti-malarials with distinct capacities to inhibit, kill and clear parasites.

Citing Articles

Antimalarial Drug Discovery from Natural and Synthetic Sources.

Mohd Azam N, Othman S, Choo Y Curr Med Chem. 2024; 32(1):87-110.

PMID: 38818916 DOI: 10.2174/0109298673312727240527064833.


Systemic host inflammation induces stage-specific transcriptomic modification and slower maturation in malaria parasites.

Lansink L, Skinner O, Engel J, Lee H, Soon M, Williams C mBio. 2023; 14(4):e0112923.

PMID: 37449844 PMC: 10470790. DOI: 10.1128/mbio.01129-23.


Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.

Gaur A, Panetta J, Smith A, Dallas R, Freeman 3rd B, Stewart T EBioMedicine. 2022; 80:104065.

PMID: 35598441 PMC: 9127571. DOI: 10.1016/j.ebiom.2022.104065.

References
1.
Croft S, Duparc S, Arbe-Barnes S, Craft J, Shin C, Fleckenstein L . Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012; 11:270. PMC: 3483207. DOI: 10.1186/1475-2875-11-270. View

2.
. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018; 391(10128):1378-1390. PMC: 5889791. DOI: 10.1016/S0140-6736(18)30291-5. View

3.
Menard D, Fidock D . Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. Lancet Infect Dis. 2019; 19(9):916-917. PMC: 6754981. DOI: 10.1016/S1473-3099(19)30394-9. View

4.
Aogo R, Khoury D, Cromer D, Elliott T, Akter J, Fogg L . Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice. Int J Parasitol. 2018; 48(12):903-913. DOI: 10.1016/j.ijpara.2018.05.010. View

5.
Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S . Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J. 2012; 11:45. PMC: 3305508. DOI: 10.1186/1475-2875-11-45. View